Funded Startups in Allston
Allston, Massachusetts punches above its size as a funding destination, with the 12 rounds shown here spanning late 2020 through mid-2025 and skewing heavi…
Allston, Massachusetts punches above its size as a funding destination, with the 12 rounds shown here spanning late 2020 through mid-2025 and skewing heavily toward biotechnology and artificial intelligence. Five biotech companies appear in the data — Gel4Med, i2o Therapeutics, Elevian, Tectonic Therapeutic, and X-COR Therapeutics — with Tectonic Therapeutic's $80M Series A (April 2021) the largest single disclosed raise, followed by i2o Therapeutics at $46M (Series A, August 2023) and Elevian at $40M (Series A, September 2021).
The AI cluster adds material deal volume: XYZ Robotics closed a $40M Series B in June 2022, Proton.ai raised $20M at Series A in January 2022, and Bullseye Biosciences completed an undisclosed round in October 2024. Hardware breaks in with Northwood Space's $30M Series A in April 2025, the most recent disclosed-amount raise in the dataset. Series A is the dominant stage across the rows shown, and two rounds — Gel4Med and Bullseye Biosciences — carry undisclosed amounts as of their filing dates.
Most recent rounds
12 shownRelated listings
Frequently asked
What are the largest disclosed rounds among these Allston startups?
Tectonic Therapeutic leads with an $80M Series A closed in April 2021, followed by i2o Therapeutics at $46M (Series A, August 2023) and two $40M rounds — Elevian's Series A in September 2021 and XYZ Robotics' Series B in June 2022. Northwood Space is the most recent large deal at $30M (Series A, April 2025).
Which sector dominates Allston funding in this dataset?
Biotechnology is the most represented sector, accounting for five of the 12 rows: Gel4Med, i2o Therapeutics, Elevian, Tectonic Therapeutic, and X-COR Therapeutics. Artificial intelligence is the second most common, with XYZ Robotics, Proton.ai, and Bullseye Biosciences all classified under AI.
What funding stages appear most frequently in these Allston rounds?
Series A is the most common stage, appearing in five rows — Northwood Space, i2o Therapeutics, Proton.ai, Elevian, and Tectonic Therapeutic. Three rounds are listed as Series Unknown, two of which (Gel4Med and Bullseye Biosciences) carry undisclosed amounts.
Are there any rounds with undisclosed amounts, and how should that affect prospecting?
Two rounds have undisclosed amounts: Gel4Med (Series Unknown, July 2025) and Bullseye Biosciences (Series Unknown, October 2024). Both are biotech and AI companies respectively, and their recency suggests active fundraising cycles worth monitoring even without public figures.
How far back does the visible funding activity in this dataset extend?
The earliest round shown is X-COR Therapeutics' $3M raise in November 2020; the most recent is Gel4Med's undisclosed round in July 2025. The dataset clusters noticeably in 2021–2022, with Northwood Space and Systole Health representing fresh 2025 activity.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.